Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Transfus Clin Biol ; 24(3): 227-231, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28669521

RESUMO

Transfusion remains a key treatment of sickle cell disease complications. However, delayed hemolytic transfusion reaction, the most serious complication of transfusion, may be life-threatening if hyperhemolysis develops. This syndrome is generally underdiagnosed because its biological and clinical features resemble those of vaso-occlusive crisis, and red blood cell antibodies are frequently absent. Further transfusions may aggravate the symptoms, leading to severe multiple organ failure and death. It is therefore essential to prevent, diagnose and treat this syndrome efficiently. Prevention is based principally on the attenuation of allo-immunization through the provision of extended-matched RBCs or the use of rituximab. However, such treatment may be insufficient. Early diagnosis might make it possible to implement specific treatments in some cases, thereby avoiding the need for secondary transfusion. Diagnosis is dependent on the knowledge of the medical staff. Finally, many treatments, including steroids, immunoglobulins, erythropoietin and eculizumab, have been used to improve outcome. Improvements in our knowledge of the specific features of DHTR in SCD should facilitate management of this syndrome.


Assuntos
Anemia Falciforme/terapia , Reação Transfusional , Corticosteroides/uso terapêutico , Anemia Falciforme/sangue , Anemia Falciforme/imunologia , Anticorpos Monoclonais Humanizados/uso terapêutico , Tipagem e Reações Cruzadas Sanguíneas , Humanos , Imunização , Isoanticorpos/sangue , Rituximab/uso terapêutico , Reação Transfusional/diagnóstico , Reação Transfusional/imunologia , Reação Transfusional/prevenção & controle , Reação Transfusional/terapia
2.
Transfus Clin Biol ; 7(1): 9-14, 2000 Feb.
Artigo em Francês | MEDLINE | ID: mdl-10730341

RESUMO

The immunologic risk associated to erythrocyte transfusions is bound to the polymorphism of blood group systems and to the respect of blood transfusion regulations. The results of three studies are presented, which were carried out respectively by the French Society of Blood Transfusion, the National Institute of Blood Transfusion and the National Haemovigilance Network. Two hundred and twenty-seven cases of immunologic accidents are analysed using the Kaplan's interpretation model and the traditional method of process analysis. The results show three critical factors in the occurrence of this type of incident: the relevance of the clinical examinations prescribed, the way in which the biological results are taken into account, and the relationship/exchange of information between private and public hospitals, and blood transfusion centers.


Assuntos
Incompatibilidade de Grupos Sanguíneos/epidemiologia , Tipagem e Reações Cruzadas Sanguíneas , Transfusão de Sangue/estatística & dados numéricos , Sistema ABO de Grupos Sanguíneos/análise , Sistema ABO de Grupos Sanguíneos/imunologia , Acidentes , Incompatibilidade de Grupos Sanguíneos/imunologia , Incompatibilidade de Grupos Sanguíneos/prevenção & controle , Transfusão de Eritrócitos/efeitos adversos , Transfusão de Eritrócitos/estatística & dados numéricos , Controle de Formulários e Registros , França , Humanos , Isoanticorpos/imunologia , Erros Médicos , Prontuários Médicos , Polimorfismo Genético , Estudos Retrospectivos , Medição de Risco , Gestão de Riscos , Reação Transfusional
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA